Literature DB >> 18243838

Natural history of hepatocellular carcinoma and current treatment options.

Jean-Luc Raoul1.   

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the most severe complication of chronic liver disease. The annual number of new cases worldwide is approximately 550,000, representing more than 5% of human cancers and is the third leading cause of cancer-related deaths. The stages of the malignancy as well as the severity of the underlying liver disease are essential factors in planning the therapeutic approach. Curative treatment options are represented mainly by surgery (ie, resection or transplantation), but most patients are not candidates for a curative option, and only palliative treatment could be given to these patients. Among palliative treatments, only chemoembolization has been proven to be effective, but other options are currently being investigated. Major risk factors for HCC are well known and are dependent on the geographic area. In Europe, the United States, and Japan, the main risk factors are liver cirrhosis, hepatitis B and C virus, alcohol, and tobacco; in contrast, in Africa and Asia, these factors are hepatitis B and C virus, tobacco use, and aflatoxin exposure. Cirrhosis from any cause is a predisposing factor for HCC and could be considered as a premalignant condition. The present concept of carcinogenesis in HCC is a multistage process. This article describes the natural history of HCC and discusses the various treatment options available at present.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243838     DOI: 10.1053/j.semnuclmed.2007.10.004

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  16 in total

Review 1.  Hepatocellular Carcinoma: Combined Transarterial Chemoembolization and Ablation.

Authors:  Josi L Herren; Nerina Disomma; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

2.  Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006.

Authors:  Chuanhui Dong; Young-Hee Yoon; Chiung M Chen; Hsiao-Ye Yi
Journal:  J Stud Alcohol Drugs       Date:  2011-11       Impact factor: 2.582

3.  Resection of a transplantable single-nodule hepatocellular carcinoma in Child-Pugh class A cirrhosis: factors affecting survival and recurrence.

Authors:  Fabrice Muscari; Bertrand Foppa; Nicolas Carrere; Nassim Kamar; Jean-Marie Peron; Bertrand Suc
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

4.  Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Ron C Gaba; Brian Jin; Robert J Lewandowski; Ahsun Riaz; Khairuddin Memon; Robert K Ryu; Kent T Sato; Laura M Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  Radiology       Date:  2014-03-28       Impact factor: 11.105

5.  Terpenoids as potential chemopreventive and therapeutic agents in liver cancer.

Authors:  Roslin J Thoppil; Anupam Bishayee
Journal:  World J Hepatol       Date:  2011-09-27

6.  Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLC-MS-MS.

Authors:  Sigrid Baumgarten; Ron C Gaba; Richard B van Breemen
Journal:  Biomed Chromatogr       Date:  2012-03-27       Impact factor: 1.902

7.  Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Chengbo Yu; Qing Cao; Ping Chen; Shigui Yang; Xianli Gong; Min Deng; Bing Ruan; Lanjuan Li
Journal:  Tumour Biol       Date:  2016-10-25

8.  Primary hepatocellular carcinoma in ectopic liver masquerading as left adrenal carcinoma: a rare occurrence.

Authors:  Vishwajeet Singh; Rahul Janak Sinha; Satya Narayan Sankhwar; Shailendra Kumar; Bandana Mehrotra; Mohini Puri; Vengetesh Kilvani Sengottayan
Journal:  Rare Tumors       Date:  2010-06-30

9.  Towards novel anti-tumor strategies for hepatic cancer: ɛ-viniferin in combination with vincristine displays pharmacodynamic synergy at lower doses in HepG2 cells.

Authors:  Filiz Özdemir; Gülşen Akalın; Mesut Şen; Nur Ipek Önder; Arzu Işcan; H Mehtap Kutlu; Zerrin Incesu
Journal:  OMICS       Date:  2013-12-17

10.  Multiple ectopic hepatocellular carcinomas arising in the abdominal cavity.

Authors:  Toru Miyake; Seiichiro Hoshino; Yoichiro Yoshida; Naoya Aisu; Syu Tanimura; Satoshi Hisano; Nobuaki Kuno; Tetsuro Sohda; Shotaro Sakisaka; Yuichi Yamashita
Journal:  Case Rep Gastroenterol       Date:  2012-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.